Gleamer and France Imageries Territoires Forge Strategic Partnership to Deploy Gleamer Copilot® Nationwide

Collaboration brings the Gleamer Copilot® solutions to more than 500 radiologists and launches a program to co-develop next-generation imaging AI applications.

PARIS, FR - 8th July 2025. 

Gleamer, a global leader in AI for medical imaging, today announced a strategic partnership with France Imageries Territoires (FIT) to roll out a selection of its Gleamer Copilot® solutions across FIT’s extensive network of imaging centres. The agreement will equip FIT’s radiologists with expert-level AI support while establishing a co-development roadmap for new clinical modules.

FIT unites over 500 radiologists organised in a physician-led governance model and provides imaging services to approximately 2.2 million patients every year across metropolitan France and overseas territories. franceimageries.fr

“With this partnership, FIT is investing in Gleamer’s unified AI Copilot that streamlines the radiology workflow,” said Christian Allouche, CEO & Co-founder of Gleamer. “Their decision validates our vision that the future of imaging lies in a unified Copilot that spans multiple modalities and can rapidly adapt to new clinical needs.”

The deployment follows Gleamer’s recent expansion of its Copilot portfolio, now covering X-ray, mammography, CT and MRI, enhanced through the acquisitions of Pixyl and Caerus Medical, making it the market’s most comprehensive proprietary CE- and FDA-cleared AI platform. gleamer.ai

“AI is only transformative when it is woven into the daily routine of radiologists,” said Xavier Lemoine, Coordinateur Général at France Imageries Territoires. “By partnering with Gleamer, we’re not just adopting best-in-class algorithms; we’re co-designing new solutions and reorganising our workflows around them to deliver faster, more equitable care for our patients.”

Under the agreement, Gleamer and FIT will:

• Implement a selection of Gleamer’s Copilot solutions across all FIT sites, providing consistent triage, decision support and structured reporting.

• Re-imagining daily practice: Together with FIT teams, we’ll reshape clinical workflows around AI to boost efficiency and consistency.

• Co-developing tomorrow’s tools: Front-line insights will feed directly into new algorithms, turning ideas into solutions in weeks, not years.

The phased rollout begins this quarter, with full national coverage expected at the end of 2025. Financial terms are not being disclosed.

About Gleamer

Founded in 2017, Gleamer considers AI to be a key solution for addressing the sharp rise in demand for medical imaging, stemming from the challenges of an ageing population, the increasing prevalence of chronic diseases, and the problems of access to healthcare. The company's suite of AI-powered solutions, across X-Ray, Mammography, CT and now, MRI, supports radiologists and clinicians in their diagnoses, thereby improving reliability and reducing the time taken to read and process examinations. The relevance and exceptional performance of these solutions have been recognised worldwide thanks to 35 publications in highly regarded peer-reviewed journals. With 40 million exams analysed across over 2,500 institutions, spanning 45 countries across all continents, Gleamer’s solutions are now widely acclaimed within the medical imaging industry. www.gleamer.ai

About France Imagerie Territoires 

The France Imageries Territoires network is a radiology network that has been developing since 2019 and has 530 French radiologists as shareholders, representing 8% of the profession. The radiologists in the network treat 2.2 million patients in 83 centres within the network, with 47 CT and MRI sites and around 80 CT and MRI scanners in operation. The network also has 19 local  centres combating medical desertification. The network also organises the treatment of 750,000 patients via tele-interpretation through its subsidiary TeleDiag, which supports 350 French healthcare establishments thanks to 700 radiologists participating in the medical project.